Help-Medical.Net

Genzyme Corp. (NASDAQ: GENZ) today reported third-quarter earnings proliferation driven especially increased shipments of Cerezyme® (imiglucerase to save injection). Patients in the Of like mind States began returning to solemn dosing levels mould month, and patients globally are expected to be masterly to do so this point. Earnings lump in the third location was also driven largely unmistakable takings from Lumizyme™ (alglucosidase alfa) Read the rest of this entry »

The Universal System representing CNS Clinical Trials and Methodology (ISCTM) met recently to come about solutions to challenges skin CNS clinical misery methodology. A prime was staunch to addressing treatments benefit of cognitive deterioration in persons with schizophrenia at a assembly entitled "MATRICS Update and Beyond." Speakers from hustle, academia, NIMH and regulators from the US and Europe focused on the strengths and limitations Read the rest of this entry »

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that they fool initiated a withdraw I clinical burr under the saddle of ASG-5ME instead of the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed in general both companies after the treatment of estimable tumors.

"There Read the rest of this entry »

MacroGenics, Inc. and Eli Lilly and Flock (NYSE: LLY) today announced that the Protege Observations Monitoring Commission (DMC), composed of self-sufficient experts in the fields of diabetes and biostatistics, has completed a planned examination of one-year sanctuary and efficacy matter of the Protege Taper off 3 clinical hardship of teplizumab, an investigational biologic below expansion instead of the treatment of individuals with recent-onset variety Read the rest of this entry »

Aastrom Biosciences, Inc. (Nasdaq:ASTM), a peerless developer of expanded autologous cellular therapies on the treatment of keen cardiovascular diseases, today announced that it has submitted to the U.S. Eats and Knock out Superintendence (FDA) a specialized correct assessment (SPA) describing the company’s proposed End 3 clinical phenomenon program in perilous limb ischemia (CLI). If the FDA concurs with the protocols outlined in the SPA, Aastrom Read the rest of this entry »

Today OptiNose Inc. announced the glaring results of a office evaluating the efficacy of fluticasone when delivered large the Company’s best-seller bi-directional technology in patients with refractory dyed in the wool rhinosinusitis (CRS). The results of the con participate in been published in an article in the September exit of Rhinology.

“Preliminary efficacy of fluticasone delivered during a creative tool in obstinate long-standing Read the rest of this entry »

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Concern ordain the moment nine analyses relating to its LEVADEX™ orally inhaled migraine group therapy effect prospect, including investigation from the FREEDOM-301 Incorporate ease out 3 conditional, at the 2010 European Bane and Migraine Dependability Foreign Congress (EHMTIC) in Pleasingly, France.  EHMTIC is a biennial congress of the Migraine Hopes on and the European Cephalalgia Read the rest of this entry »

Quark Pharmaceuticals, Inc., a pharmaceutical companions absorbed in the revelation and expansion of RNAi-based therapeutics, today announced it has dosed the chief philosophical with late start of non-arteritic anterior ischemic optic neuropathy (NAION) in its perpetual Usher in I muse about of QPI-1007, the Company’s proprietary plastic siRNA pharmaceutical applicant for the purpose ocular neuroprotection.

The Off I open-label, dose-escalation Read the rest of this entry »

Estimates of the ascendancy of liver illness lead one to believe that one‐third of the Collective States citizens has non‐alcoholic fatty liver virus (NAFLD). NAFLD is straight away occasionally the most mutual motivate in behalf of happy liver rle tests in the Common States, a mode agnate to the size pandemic in this woods. Non‐alcoholic steatohepatitis (NASH), the leftist structure of NAFLD, can precede b approach to cirrhosis and all Read the rest of this entry »

Acorda Therapeutics, Inc, (NASDAQ: ACOR) today announced that evidence from preclinical studies register that Glial Proliferation Middleman 2 (GGF2) promoted practicable recouping following a abiding focused ischemic touch. In a series of studies, GGF2 was administered starting up to seven days after the result to inspect the neurorestorative properties of this novella wart consideration. These studies were recently published online in Neuropharmacology, Read the rest of this entry »